Kraig Biocraft Laboratories Confirms Strength and Toughness of Its Commercially Produced Recombinant Spider Silk
Kraig Biocraft Laboratories (OTCQB: KBLB) has confirmed that its commercially produced recombinant spider silk matches the exceptional strength and toughness of previous small batch testing. This breakthrough opens doors for aggressive commercial production. Recent tests at the company's R&D headquarters compared samples of Kraig's spider silk against mundane silk using a high-precision tensile testing machine. The results verified the mechanical superiority of Kraig's spider silk, with no loss in strength or toughness despite the significant increase in production scale.
COO Jon Rice stated that this confirmation unlocks a scalable system for commercial sustainable spider silk production. The company is now confident to proceed with its spider silk production scale-up, potentially revolutionizing the global textile industry.
Kraig Biocraft Laboratories (OTCQB: KBLB) ha confermato che la sua seta di ragno ricombinante prodotta commercialmente corrisponde all'eccezionale resistenza e durezza riscontrate nei precedenti test in piccoli lotti. Questa innovazione apre la strada a una produzione commerciale aggressiva. Recenti test presso la sede della R&S dell'azienda hanno confrontato campioni della seta di ragno di Kraig con seta comune utilizzando una macchina di test della resistenza ad alta precisione. I risultati hanno verificato la superiorità meccanica della seta di ragno di Kraig, senza perdita di resistenza o durezza nonostante l'aumento significativo della scala di produzione.
Il COO Jon Rice ha dichiarato che questa conferma sblocca un sistema scalabile per la produzione commerciale sostenibile di seta di ragno. L'azienda è ora fiduciosa di procedere con l'aumento della produzione di seta di ragno, potenzialmente rivoluzionando l'industria tessile globale.
Kraig Biocraft Laboratories (OTCQB: KBLB) ha confirmado que su seda de araña recombinante producida comercialmente iguala la excepcional resistencia y durabilidad de pruebas previas en lotes pequeños. Este avance abre las puertas a una producción comercial agresiva. Pruebas recientes en la sede de I+D de la empresa compararon muestras de seda de araña de Kraig contra seda convencional usando una máquina de pruebas de tracción de alta precisión. Los resultados verificaron la superioridad mecánica de la seda de araña de Kraig, sin pérdida de resistencia o durabilidad a pesar del aumento significativo en la escala de producción.
El COO Jon Rice declaró que esta confirmación desbloquea un sistema escalable para la producción comercial sostenible de seda de araña. La empresa ahora tiene confianza para proceder con la expansión de la producción de seda de araña, potencialmente revolucionando la industria textil global.
Kraig Biocraft Laboratories (OTCQB: KBLB)는 상업 생산된 재조합 거미 실크가 이전의 소량 테스트에서 보여준 뛰어난 강도와 내구성에 일치한다고 확인했습니다. 이 혁신은 공격적인 상업 생산을 위한 기회를 열어줍니다. 회사의 연구개발 본사에서 최근 실시된 테스트에서는 Kraig의 거미 실크 샘플과 일반 실크 샘플을 고정밀 인장 시험기를 사용하여 비교했습니다. 결과는 Kraig의 거미 실크의 기계적 우수성을 입증했으며, 생산 규모의 상당한 증가에도 불구하고 강도나 내구성의 손실이 없었습니다.
COO인 Jon Rice는 이 확인이 상업적으로 지속 가능한 거미 실크 생산을 위한 확장 가능한 시스템을 열어준다고 밝혔습니다. 이제 회사는 거미 실크 생산의 규모 확대를 자신 있게 진행할 수 있으며, 이는 글로벌 섬유 산업에 혁신을 가져올 잠재력이 있습니다.
Kraig Biocraft Laboratories (OTCQB: KBLB) a confirmé que sa soie d'araignée recombinante produite commercialement correspond à l'exceptionnelle résistance et durabilité des tests en petites séries précédents. Cette avancée ouvre des portes à une production commerciale agressive. Des tests récents au siège de R&D de l'entreprise ont comparé des échantillons de la soie d'araignée de Kraig à de la soie ordinaire à l'aide d'une machine de test de traction haute précision. Les résultats ont vérifié la supériorité mécanique de la soie d'araignée de Kraig, sans perte de résistance ou de durabilité malgré l'augmentation significative de l'échelle de production.
Le COO Jon Rice a déclaré que cette confirmation déverrouille un système évolutif pour la production commerciale durable de soie d'araignée. L'entreprise est désormais confiante pour procéder à l'augmentation de la production de soie d'araignée, révolutionnant potentiellement l'industrie du textile mondial.
Kraig Biocraft Laboratories (OTCQB: KBLB) hat bestätigt, dass seine kommerziell produzierte rekombinante Spinnenseide der außergewöhnlichen Stärke und Zähigkeit der vorherigen Kleinserientests entspricht. Dieser Durchbruch eröffnet Möglichkeiten für eine aggressive kommerzielle Produktion. Recent tests in der Forschungs- und Entwicklungszentrale des Unternehmens verglichen Proben von Kraigs Spinnenseide mit gewöhnlicher Seide mithilfe einer hochpräzisen Zugprüfung. Die Ergebnisse bestätigten die mechanische Überlegenheit von Kraigs Spinnenseide, ohne dass dabei die Stärke oder Zähigkeit trotz der signifikanten Steigerung der Produktionsmenge verloren ging.
COO Jon Rice erklärte, dass diese Bestätigung ein skalierbares System für die kommerzielle nachhaltige Produktion von Spinnenseide freischaltet. Das Unternehmen ist nun zuversichtlich, mit der Skalierung seiner Spinnenseide-Produktion fortzufahren, was das globale Textilwesen potenziell revolutionieren könnte.
- Commercially produced spider silk matches strength and toughness of small batch testing
- Mechanical superiority of spider silk confirmed through high-precision testing
- No loss in strength or toughness despite significant increase in production scale
- Unlocks scalable system for commercial sustainable spider silk production
- Potential to revolutionize the global textile industry
- None.
ANN ARBOR, Mich., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), announces today that it has confirmed that the material performance of its commercially produced recombinant spider silk matches the exceptional strength and toughness of the Company’s previous small batch performance testing. The results of this testing open the doors for Kraig Labs to aggressively move forward with commercial production of its proprietary recombinant spider silk.
Testing was completed last week at the Company’s R&D headquarters, pitting samples of the Company's commercially produced spider silk against samples of mundane silk in a head-to-head test. Using a high-precision tensile testing machine, multiple samples of each silk type were tested using high-frequency data sampling, monitoring force, and displacement. Yield strength, ultimate tensile strength, and elongation data were collected and analyzed, confirming the mechanical superiority of the Company's spider silk.
This testing confirmed that there has been no loss in strength or toughness associated with this significant growth in production scale. While these results were expected, by Kraig Labs and its key production advisor, verifying that what works in the lab also works in the field under commercial production conditions was an important milestone.
"The results of this testing confirm the performance of our production spider silk, unlocking a scalable system for commercial sustainable spider silk production," said Company COO, Jon Rice. "Having worked with these materials for some time, we are not at all surprised by these results. We are happy to have our expectations confirmed and the added confidence to continue to aggressively move forward with our spider silk production scale-up."
To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com
FAQ
What did Kraig Biocraft Laboratories (KBLB) announce about its spider silk production?
How did Kraig Biocraft Laboratories (KBLB) test its spider silk?
What are the implications of Kraig Biocraft Laboratories' (KBLB) spider silk test results?
What did Jon Rice, COO of Kraig Biocraft Laboratories (KBLB), say about the spider silk test results?
